Vaginal Estrogen for Asymptomatic Microscopic Hematuria
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The specific aim of this protocol is to determine whether vaginal estrogen is an effective
treatment for asymptomatic microscopic hematuria in postmenopausal women. The investigators
hypothesize that women who use vaginal estrogen for three months will be more likely to have
resolution of their asymptomatic microscopic hematuria compared with women who do not use
vaginal estrogen.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Urogynecology Associates
Collaborators:
Beth Israel Deaconess Medical Center Mount Auburn Hospital